Imetelstat: a first-in-class telomerase inhibitor

A unique molecule targeting a hallmark of cancer

2017 annual meeting of stockholders

Event details are now available

A transformative approach

Disease-modifying potential in hematologic malignancies

Together we can make a difference in patients’ lives

Partnerships are key to our success

A visionary history

Creating a legacy of bold innovation